An Open-Label, Phase 1b/2 study of Surufatinib in Combination with Tislelizumab in Patients with Advanced Neuroendocrine Tumors MD Jennifer R. Eads,,MD Satya Das,,MD Daneng Li,,MD Amr Mohamed,, MBS, CCRP Christopher Tucci,,MS Shivani Nanda,, MD, FACP John S. Kauh,, MD, MBA Marek K. Kania,,MD Arvind Dasari,Endocrine Abstracts（2023）引用 0|浏览5暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
